First Trust Small Cap Core AlphaDEX Fund (FYX) Price & Chart

Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Ardent Health (ARDT) to $13.50 from $12 and keeps an Equal Weight rating on the shares. Published first on

DA Davidson raised the firm’s price target on Appian (APPN) to $60 from $42 and keeps a Neutral rating on the shares. The firm is citing the company’s positive Q3

Piper Sandler raised the firm’s price target on Xeris Biopharma (XERS) to $12 from $8 and keeps a Neutral rating on the shares following quarterly results. Management is now guiding

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Septerna (SEPN) to $65 from $51 and keeps a Buy rating on the shares, citing a belief that the company

Stephens raised the firm’s price target on Ardent Health (ARDT) to $21 from $13 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Morgan Stanley analyst Sanjit Singh raised the firm’s price target on Appian (APPN) to $57 from $32 and keeps an Equal Weight rating on the shares. An acceleration in constant

Citi raised the firm’s price target on Appian (APPN) to $69 from $40 and keeps a Buy rating on the shares. The firm views the company’s Q3 report as strong.

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $10 and keeps a Buy rating on the shares. The company’s Q3 results

Barclays analyst Manav Patnaik raised the firm’s price target on First Advantage (FA) to $34 from $30 and keeps an Overweight rating on the shares. Published first on TheFly –